-
Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
The second new Alzheimer's disease drug approved by Eli Lilly in China, following Lecanemab from Eisai/Bojian, has been launched. On December 18th, Eli Lilly and Company announced that the world's se ...